Edmonton, Alberta – Innovotech Inc. (TSXV: IOT, “Innovotech”, or the “Company”)
announces its intention to obtain a stock quotation in the United States and a trading symbol
on the OTC Markets (“OTCQB”), an over-the-counter venture market. A quotation on the
OTCQB will enhance the Company’s visibility to the investment community with the goal of
making the Company more accessible to retail and institutional investors in the United States
and to increase the liquidity of the Company.
The OTCQB quotation operates in parallel with the Company’s primary Canadian listing. The
OTCQB quotation is expected to impose no additional material compliance or reporting
requirements. As a foreign private issuer, Innovotech will continue to meet its existing
primary market disclosure obligations on SEDAR+, which satisfy OTC market requirements
under established foreign issuer exemptions. To be considered for admission to the OTCQB,
companies must meet certain financial standards, be current in their reporting obligations,
and undergo an annual verification and management certification process.
In conjunction with the listing, the Company will also apply for eligibility with the Depository
Trust Company (“DTC”), enabling simplified electronic clearing and settlement of its common
shares for U.S. investors.
About Innovotech:
Innovotech Inc. is a Canadian boutique contract research organization specializing in
advanced laboratory services and commercializing proprietary technologies. A leader in
biofilm science, the company provides expertise in antimicrobial testing, pharmaceutical
analysis, and industrial laboratory solutions, supported by innovative methodologies and
products including its widely-used MBEC Assay® kit for high-throughput antimicrobial and
antibiotic testing. Innovotech serves clients across multiple sectors, delivering customized
research and testing services designed to meet rigorous regulatory and scientific standards
such as those of the U.S. Food and Drug Administration and Health Canada through its ISOcertified
and GMP-accredited laboratories. Learn more at https://www.innovotech.ca.
Craig Milne, CEO Innovotech Inc.
+1-604-239-1819 craig.milne@innovotech.ca
This document may contain forward-looking statements that are predictive in nature and subject
to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may
differ materially from past results and those expressed or implied by any forward-looking
statements. Factors that could cause or contribute to such risks or uncertainties include, but are
not limited to: the regulatory environment including the difficulty of predicting regulatory
outcomes; changes in the value of the Canadian dollar; the Company’s reliance on a small number
of customers including government organizations; fluctuations in operating results; government
policies or actions; progress and cost of clinical trials; reliance on key strategic relationships;
uncertainty related to intellectual property protection and potential costs associated with its
defense; the Company’s exposure to lawsuits and other matters beyond the control of
management. Should known or unknown risks or uncertainties materialize, or should
management’s assumptions prove inaccurate, actual results could vary materially from those
anticipated. The Company undertakes no obligation to publicly make or update any forwardlooking
statements, except as required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is
defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy
or accuracy of this release.
